Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 95

Results For "India"

3667 News Found

Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan
Policy | February 01, 2026

Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan

The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave


Budget 2026-27: Government launches Rs. 10,000 crore Biopharma SHAKTI Scheme to build global manufacturing hub
Policy | February 01, 2026

Budget 2026-27: Government launches Rs. 10,000 crore Biopharma SHAKTI Scheme to build global manufacturing hub

A nationwide network of over 1,000 accredited clinical trial sites will be created to accelerate drug development timelines and enhance research credibility


Budget 2026–27: Rs. 1,06,530.42 crore allocated to Ministry of Health and Family Welfare
Policy | February 01, 2026

Budget 2026–27: Rs. 1,06,530.42 crore allocated to Ministry of Health and Family Welfare

The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education


Eli Lilly announces $3.5 billion Pennsylvania manufacturing hub
News | January 31, 2026

Eli Lilly announces $3.5 billion Pennsylvania manufacturing hub

The facility will bring 850 high-value jobs to the region, including engineers, scientists, operations personnel, and lab technicians


Glenmark reports robust Q3 FY26 performance, revenues surge 15% YoY
News | January 31, 2026

Glenmark reports robust Q3 FY26 performance, revenues surge 15% YoY

rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million


Aster DM Healthcare reports solid Q3 FY26 growth, combined proforma revenue up 15%
News | January 31, 2026

Aster DM Healthcare reports solid Q3 FY26 growth, combined proforma revenue up 15%

On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr


Gland Pharma reports robust Q3 FY26 results: revenue up 22%, adj. PAT soars 37%
News | January 30, 2026

Gland Pharma reports robust Q3 FY26 results: revenue up 22%, adj. PAT soars 37%

The base Gland business posted ?11,790 million in revenue, up 16% YoY


Vimta Labs reports 10% YoY growth in Q3 FY26, PAT margins hold at 17.5%
News | January 30, 2026

Vimta Labs reports 10% YoY growth in Q3 FY26, PAT margins hold at 17.5%

The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year